Multiple myeloma (MM) is a neoplasm of terminally differentiated B cells characterized by clonal expansion of malignant plasma cells. High-dose therapy with melphalan supported by transplant(s) has become a standard care, especially for patients under the age of 65 years, and can prolong survival; however, at least 70% of patients relapse and survival ranges from less than a few months to greater than 10 years. 1 The prognosis of patients with myeloma is currently best estimated using the clinical parameters such as b-2-microglobulin, albumin and LDH, cytogenetics and recently gene expression profiling 1, 2 Through gene expression profiling (GEP) studies of a large population of newly diagnosed patients with myeloma, we have reported that most myeloma tumors dysregulate at least one of the three D-type cyclins and these events are mutually exclusive. 3, 4 CCND2 is normally expressed in B-lymphocytes, especially in activated cells, but not in normal plasma cells. High expression of CCND2 is observed in tumors with immunoglobulin heavy-chain gene locus translocations involving c-MAF, MAFB or FGFR3/MMSET, but also importantly a substantial subset of tumors lacking these translocations.
3 Both c-MAF and MAFB are basic/leucine Table 1 Baseline patient characteristics according to the expression level of CCND2 and the presence or absence of spiked expression of c-MAF, MAFB or FGFR3/MMSET in patients with high expression of CCND2 zipper transcription factors of the large-MAF proto-oncogene family. Hurt et al. 5 showed that CCND2 is transcriptionally activated by c-MAF in MM. It is thought that MAFB may also trans-activate CCND2 expression. The mechanism of CCND2 overexpression in cases with FGFR3/MMSET-activating translocations is unknown. 
Letters to the Editor
Recent data have shown that dysregulation of CCND1, whether through activation via the t(11;14) translocation or ectopic expression in hyperdiploid disease, is associated with a favorable prognosis in MM. 3, 6 However, the prognostic significance of elevated expression of CCND2 expression in the context of the presence or absence of translocations has never been evaluated. Given that CCND2 activation is seen in nearly half of patients with MM, 3, 4 we sought to determine the prognostic value of its expression.
Baseline characteristics of the 351 patients are summarized with regard to the clinical and biological features in Table 1 . Gene expression data from the cohort can be found at the NIH gene expression omnibus using accession number GSE2658. Based on the expression of CCND1 or CCND3 and/or CCND2 expression signal being less than o1000, 161 patients ( Figure 1b(a) and (b) ). In order to correlate the effect of spiked expression of c-MAF, MAFB or FGFR3/MMSET on clinical outcome, we subdivided 161 patients in Group H into two groups: 67 patients with spiked expression of c-MAF, MAFB or FGFR3/MMSET ( ¼ Group H-spike) and 94 patients with no spiked expression of these genes ( ¼ Group H-non-spike). EFS and OS between patients in Group L and Group H-non-spike were similar (5-year EFS/OS; Group L vs H-non-spike; 53/65 vs 63/75%, P ¼ 0.5095/ P ¼ 0.4920), whereas patients in Group H-spike had inferior EFS and OS compared with those in Group H-non-spike. (estimated 5-year EFS/OS; Group H-spike vs H-non-spike; 13/56 vs 63/75%, Po0.0001/P ¼ 0.0129) (Figure 1B(c) and (d) ).
Expression of D-type Cyclins fluctuate periodically during cell cycle progression, and are induced by mitogenic stimulation. Aberrant constitutive activation of a D-type cyclin is thought to initiate tumorigenesis in various cancers, 7 including myeloma.
3
Although the precise cellular mechanisms through which D-type cyclin overexpression may drive human myelomagenesis remains poorly understood, their inappropriate overexpression likely contributes to the phosphorylation of retinoblastoma by cyclin-dependent kinases (Cdk) and subsequent activation of E2F target genes. 7 Despite an increased incidence of poor prognostic factors such as florescence in situ hybridization (FISH) defined gain of 1q21, del13 and hypodiploid karyotypes in patients with high expression of CCND2, this group showed similar OS compared with those who had low expression of CCND2. High expression of CCND2 was associated with a poor prognosis only in patients who had spiked expression of c-MAF, MAFB or FGFR3/MMSET. Adding thalidomide did not affect OS in our study with regard to the relation of CCND2 expression (data not shown). We found that patients in Group H-non-spike had similar EFS and OS compared with those with high expression of CCND1 (data not shown). Our data suggest that overexpression of CCND2 does not, in of itself, contribute to a more aggressive form of disease, but rather like CCND1 may be considered a 'weak' oncogene in MM. Our data suggest that CCND2 activation alone is not sufficient to drive aggressive disease. Instead, additional genes deregulated by c-MAF, MAFB and FGFR3/MMSET-activating translocations cooperate with cyclin D2 in the development of a high-risk disease. The mechanism(s) of CCND2 activation in myeloma tumors, except for cases with c-MAF activation, is still largely unknown. We found that copy number of CCND2 was not correlated with expression level of CCND2 using interphase FISH (data not shown). Interestingly, patients with an elevated expression of proliferation-associated genes tend to have high expression of CCND2 rather than the other D-type cyclins (data not shown). These data suggest that therapeutic strategies that target the Cdk4/6-cyclin D2 complex should be considered. However, these data also suggest that blocking Cdk4/6-cyclin D2 function may not be sufficient, even in patients with high expression of CCND2, because signals upstream of CCND2 may affect not only CCND2 but also other genes that contribute to more aggressive clinical course. Finally, these results must be placed in the context of a recent report suggesting that Cdk6-cyclin D2 expression is associated with aggressive disease. 8 Our data clearly demonstrate that there are two forms of disease that overexpress CCND2. One a high-risk disease associated with elevated CCND2 and the other not. Further studies are needed to clarify the mechanism of aberrant expression of CCND2 in myeloma and its context-driven association with prognosis.
